Supply disruption has cast doubt on Dr Reddy's ability to capitalise on its early lead, with brokerages warning that prolonged delay could allow competitors to gain ground, weaken pricing power and slow earnings growth
SENSEX 77,321.54
+ 579.72
NIFTY 24,123.65
+ 160.85
CRUDEOIL 6,914.00
Dr Reddy's shares crash 9% in 2 days; brokerages slash target prices after semaglutide supply disruption. What lies ahead?
Dr Reddy's shares slide 7% after delay in semaglutide supplies over quality concerns
Dr. Reddy’s to delay semaglutide supplies due to quality issue, shares hit
Dr. Reddy’s to delay semaglutide supplies due to quality isssue, shares hit
Dr. Reddy’s halts semaglutide supplies on quality concerns, shares plunge, Torrent recalls product
Dr Reddy's flags quality issue in semaglutide batches, delays commercial supplies
Dr Reddy’s pauses weight loss drug on quality fears
Dr Reddy's Laboratories shares extended their decline after the company delayed commercial supplies of its semaglutide product…
Dr Reddy's shares fell sharply on Thursday after the company delayed commercial supplies of its semaglutide product due to a…
Aurobindo Pharma surpasses Dr Reddy's in FY26 revenue, becoming the second-largest Indian pharma company.
Redington India's CEO discusses domestic manufacturing's resilience, rising memory prices, and the shift towards ecosystem…
Dr. Reddy’s delays semaglutide supplies over quality issues, causing shares to drop amid ongoing investigations and commitment to…
Dr Reddy's Laboratories anticipates a gradual recovery this fiscal year. The company faced a profit drop last year due to US…
